Issues
-
Cover Image
Cover Image
The long noncoding RNA HOXC-AS3 is activated upon glucose deprivation to trigger a switch in glucose metabolism. HOXC-AS3 selectively antagonizes SIRT6-mediated H3K9ac deacetylation of glycolysis-related genes and promotes metabolic reprogramming of breast cancers. Administration of anti-HOXC-AS3-motif-RNAs effectively blocks the function of HOXC-AS3, ultimately suppressing breast cancer progression. For details, see article by Zhu and colleagues on page 805. - PDF Icon PDF LinkTable of Contents
- PDF Icon PDF LinkEditorial Board
Cancer Research
Table of Contents
Breaking Insights
Obituary
Reviews
Cancer Research Highlights
Controversy and Consensus
Priority Reports
Antibody-Peptide Epitope Conjugates for Personalized Cancer Therapy
This study develops a high-throughput preclinical platform to identify patient-specific antibody–peptide epitope conjugates that target cancer cells and demonstrates the potential of this immunotherapy approach for treating ovarian carcinoma.
Resource Report
Genome and Epigenome
Chromatin Remodeling Induced by ARID1A Loss in Lung Cancer Promotes Glycolysis and Confers JQ1 Vulnerability
Metabolism and Chemical Biology
Molecular Cell Biology
Cancer-Associated SF3B1 Mutations Confer a BRCA-Like Cellular Phenotype and Synthetic Lethality to PARP Inhibitors
Tumor Biology and Immunology
IgA-Dominated Humoral Immune Responses Govern Patients' Outcome in Endometrial Cancer
The Roles of RNA Helicases in DNA Damage Repair and Tumorigenesis Reveal Precision Therapeutic Strategies
Translational Science
p16 Represses DNA Damage Repair via a Novel Ubiquitin-Dependent Signaling Cascade
Convergence and Technologies
Quantification of T- and B-cell Immune Receptor Distribution Diversity Characterizes Immune Cell Infiltration and Lymphocyte Heterogeneity in Clear Cell Renal Cell Carcinoma
Editor's Note
Corrections
Correction: Genetic Dissociation of Glycolysis and the TCA Cycle Affects Neither Normal nor Neoplastic Proliferation
Journal Archive
Cancer Research
(1941-Present; volumes 1-current)Published twice monthly since 1987. From 1941-1986, published monthly.
(ISSN 0008-5472)
The American Journal of Cancer
(1931-1940; volumes 15-40)Published quarterly in 1931, bimonthly in 1932, and monthly from 1933 to 1940. The journal changed title to Cancer Research in 1941.
(ISSN 0099-7374)
The Journal of Cancer Research
(1916-1930); volumes 1-14)Published quarterly from 1916 through 1930 (publication was suspended from November 1922 to March 1924). The journal changed title to The American Journal of Cancer in 1931.
(ISSN 0099-7013)
Advertisement
Email alerts
NOTICE: This notice serves to inform the reader that, in 2023, AACR received a donation by Pfizer of the rights to royalties from the sale—within the United States—of Bavencio® (avelumab), a pharmaceutical owned by Merck. None of these funds are being, or will be, used to directly support any specific publication or author. If an individual article is published that deals with this particular drug, such article will include standard financial disclosures per AACR journal policy. For more detail regarding AACR’s established policies for authors, please go to https://aacrjournals.org/pages/editorial-policies#coi.